FOURTH CONFERENCE ON DNA TOPOISOMERASES IN THERAPY

我们建议在2010年举办“第四届DNA拓扑异构酶会议”。 1992年10月17日至19日在纽约大学医学中心举行的“治疗”。 会议将 不仅讨论抗癌药物及其靶DNA拓扑异构酶I 或II，但也是一种密切相关的酶DNA促旋酶， 喹诺酮类及相关药物。 有一系列的问题，如酶， 遗传学、生物化学、作用机制和抗性， 这两个研究领域的共同点是， 有效抗感染的治疗或药剂。 编制和 会议的安排将包括： 1}通过邮件和电子邮件传播关于会议的信息 在科学期刊上刊登广告或公告。 2}会议的组织将作为三个半 一天的会议，包括九次幻灯片演示的全体会议， 两到三个海报会议。 每个幻灯片会议将邀请 演讲者，其中大多数是该领域的顶尖专家， 选定的提供的文件有三个主要议题将涵盖在 全体会议： (i)原核和真核拓扑异构酶的基础研究 和新的进展。 (ii)喹诺酮类及相关化合物，DNA促旋酶抑制剂， 感染的治疗。 (iii)新的抗癌剂，DNA拓扑异构酶I和II的抑制剂， 实验室，先进的临床前和临床研究。 3}将会议演讲作为全尺寸文章出版。 试图 将出版选定的主题作为一卷集中在 喜树碱，一类新型抗癌药物。

We propose to organize the "Fourth Conference on DNA Topoisomerases in Therapy" at the NYUMC, in October 17-19, 1992. The conference will discuss not only anticancer agents and their target DNA topoisomerase I or II, but also a closely related enzyme DNA gyrase targeted by quinolones and related drugs. There is a host of problems such as enzyme genetics, biochemistry, mechanism of action and resistance, which are common to these two fields of research either developing anticancer treatment or agents effective against infection. The preparation and organization of the conference will include: 1} Dissemination of information, regarding the conference, by mail and by advertisement or announcements in scientific journals. 2} Organization of the conference which will be held as a three-and-half day meeting, with nine plenary sessions of slide presentations, and with two to three poster sessions. Each slide session will include invited speakers, most of them leading experts in the field, and presenters of selected proffered papers There are three major topics to be covered in plenary sessions: (i) Basic research of prokaryotic and eukaryotic topoisomerases, overview and new advances. (ii) Quinolones and related compounds, inhibitors of DNA gyrase, in therapy of infection. (iii) New anticancer agents, inhibitors of DNA topoisomerase I and II, in laboratory, advanced pre-clinical and clinical research. 3} Publication of conference lectures as full-size articles. An attempt will be made to publish selected topics as a volume focussed on camptothecins, a novel class of anticancer drugs.